Background. Asthma is characterized by hyperresponsiveness of the airways to
bronchoconstrictive stimuli. Long-acting β2-adrenoceptor agonists have been introduced as …

Background. An effective, long-acting bronchodilator could benefit patients with asthma who
have symptoms not controlled by antiinflammatory drugs. We compared a new long-acting …

The recent development of new β2-adrenoceptor agonists with a duration of action in excess
of 12 h may change strategies in the treatment of bronchial asthma. This study aims at the …

Objective: We have previously found that β2-adrenoceptor downregulation and
bronchodilator desensitization to albuterol occurred at 36 hours after stopping regular …

We evaluated the profile of the bronchodilatory effect of three inhaled beta2-agonists, 24
microg formoterol, 50 microg salmeterol and 200 microg salbutamol, in patients with stable …

The aim of this study was to systematically compare the interaction of the long-acting beta2-
adrenoceptor agonists formoterol and salmeterol with short-acting beta2-adrenoceptor …

Salmeterol is a new inhaled beta 2 adrenoceptor agonist, which has been shown in animal
experiments to produce a more prolonged bronchodilator effect than currently available beta …

Objective.—To compare the efficacy and safety of inhaled salmeterol xinafoate, a long-
acting β 2-adrenoceptor agonist, with that of albuterol, a short-acting inhaled β 2-agonist, in …

Objective To review the pharmacology of the long-acting inhaled β 2-agonists, salmeterol
and formoterol, summarize results of their clinical trials, evaluate their safety records, and …

Salmeterol xinafoate is an inhaled long-acting beta2-adrenoceptor agonist recently
introduced for the treatment of asthma. Both in vitro and animal studies suggest that it may …